EVALUATION OF CANDIDATE GENETIC VARIATIONS AS PHARMACOGENETIC MARKERS FOR GLICLAZIDE AMONG FILIPINOS

Main Article Content

Elizabeth Paz-Pacheco
Eva Maria Cutiongco-de la Paz
Jose Nevado Jr.
Gabriel Jasul Jr.
May Uyking-Naranjo
Ma. Luz Vicenta Guanzon
Karell Jo Angelique Calpito
Elizabeth Laurize Alejandro
Vincent Sean Ribaya
Julius Patrick Ferrer

Abstract

INTRODUCTION
To determine the genetic polymorphisms associated with drug response to gliclazide in type 2 diabetes mellitus (T2DM).


METHODOLOGY
This was an unmatched case-control study comparing response to gliclazide. Participants were enrolled from three (3) institutions (Philippine General Hospital, Corazon Locsin Montelibano Memorial Regional Hospital and Southern Philippines Medical Center) and its surrounding communities. One hundred thirty-nine adult Filipinos with newly diagnosed T2DM were enrolled to determine the association of genetic variants in response to gliclazide. Glycosylated hemoglobin (HbA1c) collected 3 months apart was used to determine response. DNA from blood samples were genotyped using Infinium iSelect beadchips. Candidate variants were then correlated with response to gliclazide using t-test, chi-square and univariate logistic regression analysis.


PRELIMINARY RESULTS AND DISCUSSION 
Four (4) candidate genetic variants associated with response to gliclazide were revealed. The two most significant single nucleotide polymorphisms (SNP) are variants of the gene 5-hydroxytryptamine receptor 2C (HTR2C) (CC > > GC > GG: OR 28.20, 95% CI 2.59, 1,464.13; p-value 0.0015 and AA vs. GG + AG: OR 0.04, 95% CI 0.00069, 0.389; p-value 0.0015 respectively). The third SNP is a variant of the gene high mobility group 20A (HMG20A) (AA > AG > GG: OR 3.70, 95% CI 1.50, 10.03; p-value 0.0018).


CONCLUSION
The study revealed SNPs that were not previously associated with response to gliclazide. These may be further investigated and validated to identify markers for response to this medication. This will be the basis for matching of patients with the appropriate medications and hence provide improved outcomes

Downloads

Download data is not yet available.

Article Details

How to Cite
Paz-Pacheco, E., Cutiongco-de la Paz, E. M., Nevado Jr., J. ., Jasul Jr., G. ., Uyking-Naranjo, M. ., Guanzon, M. L. V., Calpito, K. J. A., Alejandro, E. L., Ribaya, V. S., & Ferrer, J. P. (2022). EVALUATION OF CANDIDATE GENETIC VARIATIONS AS PHARMACOGENETIC MARKERS FOR GLICLAZIDE AMONG FILIPINOS. Journal of the ASEAN Federation of Endocrine Societies, 34(2), 29–30. Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/1961
Section
Abstracts of Original Articles | Prediabetes, Diabetes Mellitus, Hypoglycemia
Author Biographies

Eva Maria Cutiongco-de la Paz, Institute of Human Genetics, National Institutes of Health, University of the Philippines, Manila

Philippine Genome Center, University of the Philippines,
Diliman, Quezon City, Philippines

Karell Jo Angelique Calpito, Institute of Human Genetics, National Institutes of Health, University of the Philippines, Manila

Philippine Genome Center, University of the Philippines,
Diliman, Quezon City

Elizabeth Laurize Alejandro, Institute of Human Genetics, National Institutes of Health, University of the Philippines, Manila

Philippine Genome Center, University of the Philippines,
Diliman, Quezon City

Vincent Sean Ribaya, Institute of Human Genetics, National Institutes of Health, University of the Philippines, Manila

Philippine Genome Center, University of the Philippines,
Diliman, Quezon City

Julius Patrick Ferrer, Institute of Human Genetics, National Institutes of Health, University of the Philippines, Manila

Philippine Genome Center, University of the Philippines,
Diliman, Quezon City

References

*

Most read articles by the same author(s)

1 2 3 4 5 6 > >>